Clinical Trial Readiness through the Establishment of a Pilot Filovirus Investigational Vaccine Reserve
Planned
The competition has not been announced yet.
- Deadline
- May 18,Expired
- Agreement
- Buying services
- Estimated value
- €16Mover 4 years
Brief
Health and Digital Executive Agency (HaDEA) is van plan om diensten aan te schaffen voor de voorbereiding op klinische proeven voor Filovirus-uitbraken, door een EU-gebaseerde reserve van onderzoeksvaccins tegen Marburg (MARV) en/of Ebola Sudan (SUDV) op te zetten, te testen en te onderhouden. Het doel is om de snelle inzet van kandidaat-vaccins voor hun latere ontwikkelingsfase (fase 2 en verder) te waarborgen. De maximale totale contractwaarde is 16.000.000 EUR voor een duur van 4 jaar.
Forsknings- og utviklingsvirksomhet og tilhørende konsulenttjenester
Custom Assessment Criteria
Get answers to your bid/no-bid criteria
Set them up once and Cobrief answers them in every tender
Will you bid?
The agent sets up the bid and writes the first draft. Free for 14 days.
Previous winners
Who are you up against?
The suppliers who have won similar contracts at Health and Digital Executive Agency (HaDEA) , HADEA - Health and Digital Executive Agency
From the notice
This call for tenders aims to ensure clinical trial preparedness for Filovirus outbreaks through the establishment of an EU-based reserve of investigational vaccines as a critical preparedness measure, given the sporadic yet high-consequence nature of these pathogens. Specifically, the call aims to establish, pilot and maintain an investigational reserve of Filovirus candidate vaccines against Marburg (MARV) and/or Ebola Sudan (SUDV), which – in case of an outbreak – could be used to advance their development by embedding them in outbreak-associated clinical trials, facilitated through international agreements and frameworks to support such preparedness. These provisions will allow for the rapid deployment of candidate vaccines for their later-stage development (phase 2 onwards). Tenderers will further have to ensure the rapid deployment of the investigational doses, subject to specific conditions being met (such as the occurrence of an outbreak and the expressed consent of the Contracting Authority).
Contact
hadea-procurement@ec.europa.eu- PlanningType
- 73100000Main codeResearch and experimental development services
- 73120000Experimental development services